How Pesicka was paid
$11.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Edward A. PesickaPresident & Chief Executive Officer | $1,150,000 | — | $9,560,140 | $345,000 | $102,669 | $11,157,809 |
| Jonathan A. LeonExecutive Vice President & Chief Financial Officer | $572,885 | $300,000 | $2,073,293 | — | $16,528 | $2,962,706 |
| Andrew G. LongExecutive Vice President, Chief Executive Officer, Products & Healthcare Services | $691,866 | — | $2,879,578 | — | $15,736 | $3,587,180 |
| Perry A. BernocchiExecutive Vice President, Chief Operating Officer | $644,417 | — | $2,649,205 | $119,070 | $10,913 | $3,423,605 |
| Heath H. GallowayExecutive Vice President, General Counsel & Corporate Secretary | $513,731 | $265,000 | $1,497,382 | — | $18,493 | $2,294,606 |
What changed and why
- $11.2MCEO Edward A. Pesicka received total compensation of $11,157,809 for fiscal 2025, representing an increase from the prior year total of $10,737,904.
- Transaction bonuses were awarded to key executives in recognition of their contributions in closing the divestiture of the products and healthcare services business.
- Stock awards constituted the majority of the CEO total compensation package.
- The company completed the sale of the products and healthcare services business to platinum equity on December 31, 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.